• Q2 2025 unaudited group revenue of approximately $204 million, up 63% year-over-year
• FY 2025 revenue guidance of $770 million to $800 million is reaffirmed
• Gozellix® launched in the U.S. and commercial dose deliveries commenced

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) today provided an update on its commercial and operational performance for the quarter ended 30 June 2025 (Q2 2025). Q2 2025 highlights include unaudited group revenue of approximately $204 million, up 63% year-over-year. The company reaffirmed its FY 2025 revenue guidance of $770 million to $800 million. Telix also reported the launch of Gozellix® in the U.S. and the commencement of commercial dose deliveries. Other key updates include the achievement of a key recruitment milestone in the ProstACT Global Phase 3 trial, regulatory approvals to expand the trial into China, Japan and Canada, and progress across the company's therapeutic and precision medicine pipelines. Telix also received a subpoena from the U.S. Securities and Exchange Commission (SEC) seeking various documents and information primarily relating to the company's disclosures regarding the development of its prostate cancer therapeutic candidates. Telix is fully cooperating with the SEC and the information request does not extend to the company's commercial and late-stage precision medicine products.

Telix confirms FY 2025 revenue guidance of $770 million to $800 million, reflecting revenue from Illuccix sales in jurisdictions with a marketing authorization, and 11 months of revenue contribution from RLS.